New	0	2
one	4	6
-	7	7
week	8	11
,	12	12
low	14	16
-	17	17
dose	18	21
triple	23	28
therapy	30	36
for	38	40
the	42	44
treatment	46	54
of	56	57
duodenal	59	66
ulcer	68	72
with	74	77
Helicobacter	79	90
pylori	92	97
infection	99	107
.	108	108

Antimicrobial	110	122
therapy	124	130
is	132	133
the	135	137
recommended	139	149
treatment	151	159
for	161	163
duodenal	165	172
ulcer	174	178
associated	180	189
with	191	194
Helicobacter	196	207
pylori	209	214
infection	216	224
.	225	225

The	227	229
eradication	231	241
of	243	244
bismuth	246	252
-	253	253
based	254	258
triple	260	265
therapy	267	273
with	275	278
bismuth	280	286
subcitrate	288	297
,	298	298
metronidazole	300	312
and	314	316
amoxicillin	318	328
is	330	331
limited	333	339
by	341	342
low	344	346
compliance	348	357
,	358	358
drug	360	363
resistance	365	374
and	376	378
side	380	383
-	384	384
effects	385	391
.	392	392

Two	394	396
-	397	397
week	398	401
proton	403	408
pump	410	413
inhibitor	415	423
(	425	425
PPI	426	428
)	429	429
-	430	430
based	431	435
triple	437	442
therapy	444	450
has	452	454
a	456	456
higher	458	463
eradication	465	475
rate	477	480
but	482	484
is	486	487
costly	489	494
.	495	495

This	497	500
study	502	506
was	508	510
designed	512	519
to	521	522
compare	524	530
the	532	534
efficacy	536	543
,	544	544
patient	546	552
compliance	554	563
and	565	567
cost	569	572
of	574	575
short	577	581
-	582	582
term	583	586
PPI	588	590
-	591	591
based	592	596
triple	598	603
therapy	605	611
with	613	616
those	618	622
of	624	625
bismuth	627	633
-	634	634
based	635	639
triple	641	646
therapy	648	654
.	655	655

Ninety	657	662
patients	664	671
with	673	676
active	678	683
duodenal	685	692
ulcer	694	698
disease	700	706
and	708	710
H	712	712
pylori	714	719
infection	721	729
,	730	730
proven	732	737
with	739	742
the	744	746
13C	748	750
-	751	751
urea	752	755
breath	757	762
test	764	767
and	769	771
CLO	773	775
test	777	780
(	782	782
Campylobacter	783	795
-	796	796
like	797	800
organism	802	809
test	811	814
)	815	815
were	817	820
treated	822	828
randomly	830	837
in	839	840
three	842	846
therapeutic	848	858
groups	860	865
:	866	866
Group	868	872
A	874	874
,	875	875
DeNol	877	881
120	883	885
mg	887	888
,	889	889
amoxicillin	891	901
500	903	905
mg	907	908
and	910	912
metronidazole	914	926
250	928	930
mg	932	933
four	935	938
times	940	944
a	946	946
day	948	950
orally	952	957
for	959	961
14	963	964
days	966	969
;	970	970
Group	972	976
B	978	978
,	979	979
omeprazole	981	990
20	992	993
mg	995	996
plus	998	1001
clarithromycin	1003	1016
500	1018	1020
mg	1022	1023
twice	1025	1029
a	1031	1031
day	1033	1035
and	1037	1039
amoxicillin	1041	1051
500	1053	1055
mg	1057	1058
four	1060	1063
times	1065	1069
a	1071	1071
day	1073	1075
for	1077	1079
14	1081	1082
days	1084	1087
;	1088	1088
Group	1090	1094
C	1096	1096
,	1097	1097
omeprazole	1099	1108
20	1110	1111
mg	1113	1114
,	1115	1115
clarithromycin	1117	1130
250	1132	1134
mg	1136	1137
and	1139	1141
metronidazole	1143	1155
500	1157	1159
mg	1161	1162
twice	1164	1168
a	1170	1170
day	1172	1174
for	1176	1178
seven	1180	1184
days	1186	1189
.	1190	1190

Nizatidine	1192	1201
150	1203	1205
mg	1207	1208
twice	1210	1214
a	1216	1216
day	1218	1220
was	1222	1224
given	1226	1230
continuously	1232	1243
following	1245	1253
the	1255	1257
end	1259	1261
of	1263	1264
anti	1266	1269
-	1270	1270
H	1271	1271
pylori	1273	1278
therapy	1280	1286
for	1288	1290
each	1292	1295
group	1297	1301
.	1302	1302

Two	1304	1306
months	1308	1313
later	1315	1319
,	1320	1320
endoscopy	1322	1330
,	1331	1331
the	1333	1335
CLO	1337	1339
test	1341	1344
and	1346	1348
13C	1350	1352
-	1353	1353
urea	1354	1357
breath	1359	1364
test	1366	1369
were	1371	1374
repeated	1376	1383
to	1385	1386
assess	1388	1393
the	1395	1397
eradication	1399	1409
rate	1411	1414
of	1416	1417
H	1419	1419
pylori	1421	1426
and	1428	1430
the	1432	1434
ulcer	1436	1440
-	1441	1441
healing	1442	1448
rate	1450	1453
.	1454	1454

Drug	1456	1459
tolerance	1461	1469
was	1471	1473
evaluated	1475	1483
by	1485	1486
patients	1488	1495
themselves	1497	1506
by	1508	1509
daily	1511	1515
recording	1517	1525
of	1527	1528
any	1530	1532
side	1534	1537
-	1538	1538
effects	1539	1545
.	1546	1546

Eighty	1548	1553
-	1554	1554
four	1555	1558
patients	1560	1567
completed	1569	1577
the	1579	1581
entire	1583	1588
course	1590	1595
of	1597	1598
therapy	1600	1606
and	1608	1610
evaluation	1612	1621
for	1623	1625
H	1627	1627
pylori	1629	1634
infection	1636	1644
.	1645	1645

The	1647	1649
H	1651	1651
pylori	1653	1658
eradication	1660	1670
rates	1672	1676
in	1678	1679
Groups	1681	1686
A	1688	1688
,	1689	1689
B	1691	1691
and	1693	1695
C	1697	1697
were	1699	1702
75	1704	1705
%	1706	1706
(	1708	1708
21	1709	1710
/	1711	1711
28	1712	1713
)	1714	1714
,	1715	1715
93	1717	1718
%	1719	1719
(	1721	1721
26	1722	1723
/	1724	1724
28	1725	1726
)	1727	1727
and	1729	1731
89	1733	1734
%	1735	1735
(	1737	1737
25	1738	1739
/	1740	1740
28	1741	1742
)	1743	1743
,	1744	1744
respectively	1746	1757
(	1759	1759
p	1760	1760
=	1762	1762
0	1764	1764
.	1765	1765
466	1766	1768
)	1769	1769
.	1770	1770

The	1772	1774
ulcer	1776	1780
healing	1782	1788
rate	1790	1793
was	1795	1797
86	1799	1800
%	1801	1801
(	1803	1803
24	1804	1805
/	1806	1806
28	1807	1808
)	1809	1809
in	1811	1812
Group	1814	1818
A	1820	1820
and	1822	1824
89	1826	1827
%	1828	1828
(	1830	1830
25	1831	1832
/	1833	1833
28	1834	1835
)	1836	1836
in	1838	1839
Groups	1841	1846
B	1848	1848
and	1850	1852
C	1854	1854
(	1856	1856
p	1857	1857
=	1859	1859
0	1861	1861
.	1862	1862
764	1863	1865
)	1866	1866
.	1867	1867

A	1869	1869
total	1871	1875
of	1877	1878
74	1880	1881
patients	1883	1890
(	1892	1892
88	1893	1894
%	1895	1895
)	1896	1896
were	1898	1901
free	1903	1906
from	1908	1911
symptoms	1913	1920
at	1922	1923
the	1925	1927
end	1929	1931
of	1933	1934
the	1936	1938
triple	1940	1945
therapy	1947	1953
.	1954	1954

Symptom	1956	1962
relief	1964	1969
was	1971	1973
faster	1975	1980
in	1982	1983
patients	1985	1992
with	1994	1997
PPI	1999	2001
-	2002	2002
based	2003	2007
triple	2009	2014
therapy	2016	2022
(	2024	2024
Groups	2025	2030
B	2032	2032
and	2034	2036
C	2038	2038
)	2039	2039
(	2041	2041
days	2042	2045
3	2047	2047
and	2049	2051
4	2053	2053
)	2054	2054
than	2056	2059
for	2061	2063
patients	2065	2072
with	2074	2077
bismuth	2079	2085
-	2086	2086
based	2087	2091
triple	2093	2098
therapy	2100	2106
(	2108	2108
day	2109	2111
5	2113	2113
)	2114	2114
.	2115	2115

The	2117	2119
cost	2121	2124
of	2126	2127
Group	2129	2133
C	2135	2135
therapy	2137	2143
was	2145	2147
lower	2149	2153
than	2155	2158
that	2160	2163
for	2165	2167
Groups	2169	2174
A	2176	2176
and	2178	2180
B	2182	2182
.	2183	2183

There	2185	2189
were	2191	2194
no	2196	2197
major	2199	2203
side	2205	2208
-	2209	2209
effects	2210	2216
in	2218	2219
any	2221	2223
of	2225	2226
the	2228	2230
patients	2232	2239
.	2240	2240

One	2242	2244
-	2245	2245
week	2246	2249
triple	2251	2256
therapy	2258	2264
with	2266	2269
omeprazole	2271	2280
,	2281	2281
clarithromycin	2283	2296
and	2298	2300
metronidazole	2302	2314
is	2316	2317
highly	2319	2324
effected	2326	2333
for	2335	2337
the	2339	2341
eradication	2343	2353
of	2355	2356
H	2358	2358
pylori	2360	2365
.	2366	2366

A	2368	2368
therapeutic	2370	2380
regime	2382	2387
of	2389	2390
one	2392	2394
week	2396	2399
'	2400	2400
s	2401	2401
duration	2403	2410
with	2412	2415
lower	2417	2421
cost	2423	2426
,	2427	2427
good	2429	2432
compliance	2434	2443
and	2445	2447
mild	2449	2452
side	2454	2457
-	2458	2458
effects	2459	2465
may	2467	2469
offer	2471	2475
a	2477	2477
good	2479	2482
choice	2484	2489
for	2491	2493
treatment	2495	2503
of	2505	2506
duodenal	2508	2515
ulcer	2517	2521
associated	2523	2532
with	2534	2537
H	2539	2539
pylori	2541	2546
infection	2548	2556
in	2558	2559
clinical	2561	2568
practice	2570	2577
.	2578	2578
